Beijing, September 03 -- Viriom Inc. (Viriom) will present its innovative medicines for treatment and prophylaxis of HIV and announce the plan for accessing Chinese market at the international China BioMed Innovation and Investment Conference (CBIIC). The CBIIC will be held in Suzhou on September 18-20.
Since 2016, the CBIIC gathers vast audiences of medical professionals and investment companies; in 2018, it will bring more than 3,500 participants, 700 pharmaceutical companies, 500 financial institutions, including experts in the pharmaceutical industry, officials, media representatives, to discuss solutions for Chinese Healthcare and Pharma industry. The 2018 conference will establish more than 10 parallel sessions in the Suzhou Industrial Park, and promises to be "the most influential event in the world for pharmaceutical innovation and investment in Asia." The organization team includes a board of investor groups, China Pharmaceutical Innovation and Research Development Association (PhiRDA), China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee, various research centers. This is the perfect platform for Viriom global team to meet current and future regional partners, share an international experience and, bring more development and product insight about Viriom’s HIV line of products to healthcare community and its patients.
One of the leading products of Viriom Inc. is elsulfavirine (aka ESV, brand name Elpida® a once daily 20mg capsules, best in class non-nucleoside reverse transcriptase inhibitor to block HIV replication), Viriom licensed Elida from Roche in 2009. Based on the positive clinical result from a 48-week, multi-center clinical trial, followed by 96-100 week pivotal study, Viriom Inc. launched and continues to launch Elpida in several developing markets expecting to treat over 8000 HIV patients in 2017-2018. Elpida, elsulfavirine based fixed dose combinations and elsulfavirine once weekly dosing regimen are undergoing market registration and development in several countries including Thailand and USA. According to the new rules for innovative drugs established by CFDA, Elpida has a potential to obtain market authorization in China via fast track.
Viriom Inc. is a commercial and late-stage development biotech company researching, manufacturing and distributing novel and affordable therapies and prophylaxis against life-threatening infections such as HIV and HBV. Viriom holds a an exclusive worldwide license from F. Hoffmann-La Roche for elsulfavirine to treat HIV1 infection, and long acting injectable VM1500A drug candidate for treatment and prevention of HIV infection in high-risk patient populations. Viriom is also developing proprietary dual and triple fixed dose regimens; VM3500 a long acting integrase strand transfer inhibitor drug candidate for treatment of HIV1 infection and VM2500 a potentially best in class pro-drug tenofovir for treatment of HIV and HBV infections. Viriom established its China subsidiary in Beijing in June 2018 and started to register its products in Chinese FDA.
For more information, please visit https://www.viriom.com/home-cn/
PR manager Xi Ailing